Accordingly, concurrent inactivation of these, using, for example, anti-AR or anti-ER agents widely used for the treatment of other pathologic conditions such as prostate and breast cancers, is anticipated to improve patient outcomes via sensitizing the efficacy of the conventional therapy, in addition to direct inhibitory effects of androgen/estrogen deprivation. Here, ESR1 is linked to breast carcinoma.